Long-term Follow-Up for RGX-121
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-121
Sponsor: REGENXBIO Inc.
Listed as NCT04597385, this observational or N/A phase trial focuses on Mucopolysaccharidosis II and remains ongoing. Sponsored by REGENXBIO Inc., it has been updated 9 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Nov 2025 — Present [monthly]
Unknown
Status: Enrolling By Invitation → Unknown
-
Sep 2024 — Nov 2025 [monthly]
Enrolling By Invitation
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation
-
Oct 2022 — Jul 2024 [monthly]
Enrolling By Invitation
-
Sep 2021 — Oct 2022 [monthly]
Enrolling By Invitation
▶ Show 4 earlier versions
-
Apr 2021 — Sep 2021 [monthly]
Enrolling By Invitation
-
Feb 2021 — Apr 2021 [monthly]
Enrolling By Invitation
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- REGENXBIO Inc.
For direct contact, visit the study record on ClinicalTrials.gov .